retinitis pigmentosa
Ocugen to Expand Phase III Gene Therapy Study in Retinitis Pigmentosa to Canada
The Phase III trial is evaluating the gene therapy, OCU400, in retinitis pigmentosa patients with RHO gene mutations and in a gene-agnostic cohort.
Ocugen Launches Expanded Access Program for Retinitis Pigmentosa Gene Therapy
Certain patients with early intermediate-to-advanced disease will be able to get OCU400 outside of a clinical trial.
Beacon Therapeutics Raises $170M in Series B Financing
The funds will support development of a gene therapy for X-linked retinitis pigmentosa, the firm's lead asset currently in a registrational trial.
Beacon Therapeutics Begins Registrational Gene Therapy Trial in Rare Retinal Disorder
The firm plans to submit data from the VISTA trial to regulatory authorities and seek AGTC-501's approval for treating X-linked retinitis pigmentosa.
EyeDNA Looking to Carve Out Regulatory Path for Retinitis Pigmentosa Gene Therapy
Based on the strength of Phase I/II data on HORA-PDE6B, the firm wants to discuss advancing the agent to a registrational study.